

Anti-NAG-1 (H variant specific) (RABBIT) Antibody NAG-1 Antibody Catalog # ASR5455

Specification

Anti-NAG-1 (H variant specific) (RABBIT) Antibody - Product Information

Host Conjugate Target Species Reactivity Clonality Application Application Note	Rabbit Unconjugated Human Human Polyclonal WB, IHC, E, I, LCI Anti-NAG1 affinity purified antibody is tested for use in ELISA and suitable for western blotting assays. This reagent is particularly useful to differentiate polymorphic forms of NAG-1 protein present in human serum samples. This antibody is useful in dual antibody immunometric assays (EIA). Specific conditions for reactivity should be optimized by the end user.
Physical State Buffer	Liquid (sterile filtered) 0.02 M Potassium Phosphate, 0.15 M
Immunogen	Sodium Chloride, pH 7.2 This affinity purified antibody was prepared by repeated immunizations with a synthetic peptide corresponding to a region near the amino terminal end of human NAG-1 protein. A residue of cysteine was added to facilitate coupling to KLH.
Preservative	0.01% (w/v) Sodium Azide

Anti-NAG-1 (H variant specific) (RABBIT) Antibody - Additional Information

Gene ID 9518

Other Names 9518

Purity

This product was affinity purified from monospecific antiserum by immunoaffinity chromatography. This antibody specifically reacts with an H variant sequence of human NAG-1 protein from human tissues. A BLAST analysis was used to suggest partial reactivity with NAG-1 from chimpanzee and macaque based on a 92% homology. Cross-reactivity with NAG-1 from other sources has not been determined.

Storage Condition

Store vial at -20° C prior to opening. Aliquot contents and freeze at -20° C or below for extended



storage. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.

Precautions Note

This product is for research use only and is not intended for therapeutic or diagnostic applications.

Anti-NAG-1 (H variant specific) (RABBIT) Antibody - Protein Information

Name GDF15 {ECO:0000303|PubMed:23468844, ECO:0000312|HGNC:HGNC:30142}

Function

Hormone produced in response to various stresses to confer information about those stresses to the brain, and trigger an aversive response, characterized by nausea, vomiting, and/or loss of appetite (PubMed: 23468844, PubMed:24971956, PubMed:28846097, PubMed:28846098, PubMed:28846099, PubMed:28953886, PubMed:29046435, PubMed:30639358, PubMed:31875646, PubMed:33589633, PubMed:38092039). The aversive response is both required to reduce continuing exposure to those stresses at the time of exposure and to promote avoidance behavior in the future (PubMed: 30639358, PubMed:33589633, PubMed:38092039). Acts by binding to its receptor, GFRAL, activating GFRAL-expressing neurons localized in the area postrema and nucleus tractus solitarius of the brainstem (PubMed: 28846097, PubMed:28846098, PubMed:28846099, PubMed:28953886, PubMed:31535977). It then triggers the activation of neurons localized within the parabrachial nucleus and central amygdala, which constitutes part of the 'emergency circuit' that shapes responses to stressful conditions (PubMed:28953886). The GDF15-GFRAL signal induces expression of genes involved in metabolism, such as lipid metabolism in adipose tissues (PubMed:31402172). Required for avoidance behavior in response to food allergens: induced downstream of mast cell activation to promote aversion and minimize harmful effects of exposure to noxious substances (By similarity). In addition to suppress appetite, also promotes weight loss by enhancing energy expenditure in muscle: acts by increasing calcium futile cycling in muscle (By similarity). Contributes to the effect of metformin, an anti-diabetic drug, on appetite reduction and weight loss: produced in the kidney in response to metformin treatment, thereby activating the GDF15-GFRAL response, leading to reduced appetite and weight (PubMed:31875646, PubMed:37060902). The contribution of GDF15 to weight loss following metformin treatment is however limited and subject to discussion (PubMed:36001956). Produced in response to anticancer drugs, such as



camptothecin or cisplatin, promoting nausea, vomiting and contributing to malnutrition (By similarity). Overproduced in many cancers, promoting anorexia in cancer (cachexia) (PubMed:32661391). Responsible for the risk of nausea and vomiting during pregnancy: high levels of GDF15 during pregnancy, mostly originating from the fetus, are associated with increased nausea and vomiting (PubMed:38092039). Maternal sensitivity to nausea is probably determined by pre-pregnancy exposure to GDF15, women with naturally high level of GDF15 being less susceptible to nausea than women with low levels of GDF15 before pregnancy (PubMed:38092039" target="_blank">31402172" target="_blank">3140217

Cellular Location Secreted Note=Secreted in the plasma.

Tissue Location


Detected in plasma (at protein level) (PubMed:28572090, PubMed:29046435). Highly expressed in placenta, with lower levels in prostate and colon and some expression in kidney (PubMed:37060902, PubMed:9348093).

Anti-NAG-1 (H variant specific) (RABBIT) Antibody - Protocols

Provided below are standard protocols that you may find useful for product applications.

- <u>Western Blot</u>
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- <u>Cell Culture</u>

Anti-NAG-1 (H variant specific) (RABBIT) Antibody - Images



In this sandwich ELISA, NAG-1 was captured from human serum using the following antibodies (see Related Products below): anti-NAG-1/GDF15 (C terminal specific), anti-NAG-1/GDF15 (N



terminal specific (PAN)), anti-NAG-1/GDF15 (H-variant) and anti-NAG-1/GDF15 (D-variant) polyclonal antibodies. Micro titer plates were coated with capture antibody at 1 µg/mL. Control plates received PBS only (data not shown). After overnight incubation and blocking, independent experiments using 20 random normal human sera were performed. Neat normal sera were applied and incubated for 1 h at 37 °C. After washing, HRP conjugated anti-NAG-1/GDF15 (C terminal specific) antibody was added for detection at 100 µL per well at 1 µg/mL. Following further incubation for 1 hr at 37°C, the plates were washed and TMBE was added as an HRP substrate for 30 min. The reaction was stopped by 1 M H2SO4 and values were measured at 450nm.

Anti-NAG-1 (H variant specific) (RABBIT) Antibody - Background

Non-steroidal anti-inflammatory drug (NSAID) activated gene (NAG-1) is a member of the transforming growth factor-beta (TGF-beta) superfamily. NAG-1 is also known as Macrophage Inhibitory Cytokine-1 (MIC-1), Growth Differentiation Factor 15 (GDF15), Placental Bone Morphogenetic Protein (PLAB), or Prostate Derived Factor (PDF). NAG-1 is expressed in human placenta, prostate and colon. It possesses antitumorigenic and proapoptotic activities. NAG-1 expression is dramatically increased in inflammation, injury and malignancy. Increase of NAG-1 expression is a feature of many cancers including breast, colon, pancreas and prostate. In a number of studies, NAG-1 expression was increased by a number of NSAIDs. This increase in expression may correlate with the chemopreventive effect NSAIDs seem to have with certain cancers. NAG-1 expression is also induced by PPAR gamma ligands and by several dietary compounds such as conjugated linoleic acids (CLAs), naturally occurring fatty acids in ruminant food products, indoles, epicatechin gallate, and genistein. Induced expression of NAG-1 results in stimulation of apoptosis and inhibition of cell growth. Inhibition of NAG-1 induced expression by small interference RNA (siRNA) results in repression of induced apoptosis. NAG-1 expression is regulated by a numbers of transcription factors such as ERG-1 and Sp1. EGR-1 may be necessary for NSAID-induced NAG-1 expression. The study of expression of NAG-1 proteins, including variants, is important to define their potential role as serum biomarkers for cancer diagnosis, treatment monitoring, epidemiology study, and nutrition surveys.